ABL Bio Past Earnings Performance
Past criteria checks 0/6
ABL Bio's earnings have been declining at an average annual rate of -182.5%, while the Biotechs industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 2.6% per year.
Key information
-182.5%
Earnings growth rate
-182.0%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | -2.6% |
| Return on equity | -3.6% |
| Net Margin | -4.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How ABL Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 65,547 | -2,647 | 13,493 | 52,035 |
| 30 Sep 23 | 67,446 | -7,951 | 14,661 | 53,845 |
| 30 Jun 23 | 97,254 | 23,608 | 14,275 | 53,925 |
| 31 Mar 23 | 104,803 | 36,101 | 14,719 | 52,347 |
| 31 Dec 22 | 67,301 | 3,209 | 15,569 | 48,416 |
| 30 Sep 22 | 57,994 | 4,352 | 14,379 | 45,801 |
| 31 Dec 21 | 5,332 | -43,558 | 13,279 | 41,034 |
Quality Earnings: A298380 is currently unprofitable.
Growing Profit Margin: A298380 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if A298380's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare A298380's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A298380 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (28.8%).
Return on Equity
High ROE: A298380 has a negative Return on Equity (-3.57%), as it is currently unprofitable.